New direction for Blaine Pharmaceuticals
CINCINNATI, Nov. 12 /CNW/ -- Blaine Pharmaceuticals announced today that
it has promoted Mark Rinker to Vice President of Sales. Mark will be
responsible for all trade relations, market development activities, and sales
management as well as evaluating and developing new products to complement the
existing Blaine product portfolio.
During his tenure at Blaine Pharmaceuticals, the company has gained
significant ground as an over-the-counter (OTC) pharmaceutical company.
Blaine's leading product, Mag-Ox 400(R), has expanded distribution in all
major food, drug, and mass channels. In 2006, DiaSense(R), a branded line of
diabetes supplements was introduced. In 2007, ReliaDose(R) (innovative
pediatric medicine delivery system) has been placed in over 27,000 retail
locations in the U.S. and internationally.
Mark was hired by Blaine Pharmaceuticals as the Director of International
Sales where he helped catapult the company's international presence for Mag-Ox
400(R), DiaSense(R), and ReliaDose(R), in Canada, Japan, South Africa, Central
America, Mexico and Korea. Since Mark has been highly involved with the
strategic direction of Blaine for the last year, he is armed with knowledge
that will be critical in his new position of Vice President of Sales.
Prior to Blaine, Mark served as director of Canadian operations for Omron
Healthcare. At Omron, Rinker successfully established Canadian operations.
Prior to Omron, Rinker served as a national sales manager with Magna-Pak,
Inc., and as a business development manager at Becton Dickinson Canada. Mark
graduated from University of Western Ontario with a Bachelor of
With his new position, Mark will report to Vince Gilday, the Chief
Operating Officer. In his new capacity he will work closely with Dreama Kirby,
the Chief Marketing Officer to set a strategic direction which focuses on
expanding Blaine's market share for its lead products. Now that Blaine has
secured significant retail distribution, its objective is to drive the sales
of these branded products with considerably more marketing support. These
changes within the organization will allow for unprecedented growth of its
brands over the next year.
About Blaine Pharmaceuticals
Blaine Pharmaceuticals, founded in 1955, specializes in the development
and acquisition of consumer brands with significant value and unrealized
potential. Blaine builds sustainable brands by creating consumer demand
through recommendations from healthcare professionals. The company's flagship
product, Mag-Ox 400(R), is the #1 selling magnesium brand. Other products
include the DiaSense(R) family of nutritional supplements and ReliaDose(R), a
pediatric medicine-delivery system.
Blaine is committed to cultivating relationships with physicians,
pharmacists, patients, wholesalers, retailers, and business partners to build
brands and lay the foundation for future endeavors. For more information,
visit www.blainepharma.com .
For further information:
For further information: Shannon Keeney, Blaine Pharmaceuticals,
+1-859-344-9600 x24, firstname.lastname@example.org Web Site: